Holen Sie sich die Stockscreener-App
878.49
0.65%
-5.71
Schlusskurs vom Vortag:
$884.20
Offen:
$881.79
24-Stunden-Volumen:
314.81K
Relative Volume:
0.97
Marktkapitalisierung:
$54.63B
Einnahmen:
$4.16B
Nettoeinkommen (Verlust:
$1.29B
KGV:
44.86
EPS:
19.5837
Netto-Cashflow:
$734.26M
1W Leistung:
-0.62%
1M Leistung:
+9.90%
6M Leistung:
+3.18%
1J Leistung:
+59.37%
1-Tages-Spanne:
$869.85
$885.07
1-Wochen-Bereich:
$861.26
$911.88
52-Wochen-Spanne:
$510.06
$934.62
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, REGN, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-12-18 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-11-24 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-09-15 | Fortgesetzt | Truist | Buy |
| 2025-09-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-08-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-08 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-05-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-03-17 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2025-03-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2025-01-17 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-11-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-11-05 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2024-11-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-11-01 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Strong Buy |
| 2024-10-04 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-08-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-07-25 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-07-23 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2023-12-20 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2023-12-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-07-31 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-24 | Herabstufung | UBS | Buy → Neutral |
| 2023-07-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-06-15 | Eingeleitet | Societe Generale | Sell |
| 2023-05-31 | Eingeleitet | UBS | Buy |
| 2023-04-25 | Eingeleitet | Citigroup | Buy |
| 2023-03-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-12-07 | Eingeleitet | William Blair | Outperform |
| 2022-10-12 | Eingeleitet | Oppenheimer | Perform |
| 2022-07-29 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-06-28 | Fortgesetzt | Stifel | Buy |
| 2022-05-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-10-29 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-28 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-23 | Hochstufung | Redburn | Neutral → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-23 | Eingeleitet | Deutsche Bank | Hold |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-06-18 | Eingeleitet | UBS | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2021-04-23 | Eingeleitet | Redburn | Neutral |
| 2021-03-05 | Bestätigt | H.C. Wainwright | Neutral |
| 2021-02-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-01-04 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-07-29 | Eingeleitet | H.C. Wainwright | Neutral |
| 2020-02-10 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-10-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-10-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-27 | Eingeleitet | Wells Fargo | Market Perform |
| 2019-09-16 | Fortgesetzt | Cowen | Outperform |
| 2019-06-28 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-18 | Fortgesetzt | SunTrust | Buy |
| 2019-01-04 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-12-17 | Eingeleitet | Goldman | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-06-29 | Eingeleitet | Nomura | Buy |
| 2018-04-09 | Eingeleitet | SunTrust | Buy |
| 2018-01-29 | Bestätigt | JMP Securities | Mkt Outperform |
Alle ansehen
Argen X Se Adr Aktie (ARGX) Neueste Nachrichten
Argenx SE Stock (NL0010832176): Analyst price target move puts biotech in focus - AD HOC NEWS
European ADRs Rose In US Trading As Biotech Led - Finimize
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Benzinga
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sahm
Sanofi Scraps Its Argenx Rival; Why Another Biotech Took The Hit - Investor's Business Daily
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know - TradingView
ARGX Stock Price, Quote & Chart - ChartMill
Argenx (ARGX) Soars 5.8%: Is Further Upside Left in the Stock? - Yahoo Finance
argenx Touts VYVGART Growth, 50,000-Patient Goal at William Blair Conference - Barchart.com
ARGX News | ARGENX SEADR (NASDAQ:ARGX) - ChartMill
H.C. Wainwright reiterates Buy on argenx stock, $940 target - Investing.com UK
H.C. Wainwright reiterates Buy on argenx stock, $940 target By Investing.com - Investing.com South Africa
Form 6K argenx NV ADR For: 3 June By Investing.com - Investing.com India
ARGX.BR Stock Price, Quote & Chart | ARGENX SE (EBR:ARGX) - ChartMill
Stifel raises argenx stock price target on myositis study outlook - Investing.com UK
Stifel raises argenx stock price target on myositis study outlook By Investing.com - Investing.com Australia
Barlow’s Research Roundup: RBC analyst provides praise and top picks in regulated utilities sector - The Globe and Mail
Argenx SE stock (NL0010832176): autoimmune drug specialist in focus after recent price strength - AD HOC NEWS
Evercore ISI Raises its Price Target on argenx (ARGX) - Yahoo Finance
Jefferies updates franchise picks list, adding AMZN, APP, MCD and more - MSN
argenx SE’s SWOT analysis: stock gains momentum on Vyvgart growth By Investing.com - Investing.com Nigeria
argenx SE’s SWOT analysis: stock gains momentum on Vyvgart growth - Investing.com
argenx SE (ARGX) Stock Price, Trades & News - GuruFocus
Argenx SE stock (NL0010832176): FMR LLC boosts stake amid price gains - AD HOC NEWS
Earnings call transcript: Argenx Q1 2026 beats EPS expectations, stock dips - Investing.com
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease - Sahm
argenx stock gains after FDA expands MG treatment approval By Investing.com - Investing.com South Africa
argenx stock gains after FDA expands MG treatment approval - Investing.com
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG - ChartMill
RBC Capital maintains argenx stock price target at $890 on uptake potential - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 By Investing.com - Investing.com Australia
Earnings call transcript: Argenx beats EPS forecast in Q1 2026 - Investing.com
Argenx beats profit forecasts despite revenue miss - Investing.com
Argenx beats profit forecasts despite revenue miss By Investing.com - Investing.com Canada
Finanzdaten der Argen X Se Adr-Aktie (ARGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):